In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on Cryolife (CRY), with a price target of $32. The company’s shares opened today at $26.70.
Kalia commented:
“We note that our EPS is GAAP and does not jibe with company guidance. Introducing FY20 numbers @ $306M & $0.13, respectively.”
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 12.7% and a 58.6% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Strata Skin Sciences Inc, and Obalon Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cryolife with a $32 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.05 and a one-year low of $17.45. Currently, Cryolife has an average volume of 134.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments.
